Abstract
Modelling COVID-19 transmission at live events and public gatherings is essential to evaluate and control the probability of subsequent outbreaks. Model estimates can be used to inform event organizers about the possibility of super-spreading and the predicted efficacy of safety protocols, as well as to communicate to participants their personalised risk so that they may choose whether to attend. Yet, despite the fast-growing body of literature on COVID transmission dynamics, current risk models either neglect contextual information on vaccination rates or disease prevalence or do not attempt to quantitatively model transmission, thus limiting their potential to provide insightful estimates. This paper attempts to bridge this gap by providing informative risk metrics for live public events, along with a measure of their associated uncertainty. Starting with a thorough review of the literature and building upon existing models, our approach ties together three main components: (a) reliable modelling of the number of infectious cases at the time of the event, (b) evaluation of the efficiency of pre-event screening and risk mitigation protocols, and (c) modelling the transmission dynamics during the event. We demonstrate how uncertainty in the input parameters can be included in the model using Monte Carlo simulations. We discuss the underlying assumptions and limitations of our approach and implications for policy around live events management.
Competing Interest Statement
JK is a co-founder and Medical Director at Certific.
Funding Statement
The work of TE has been supported by the Estonian Research Council Grant PRG1291. MH and AEL are supported in part by the NW London NIHR Applied Research Collaboration. Imperial College London is grateful for support from the NW London NIHR Applied Research Collaboration and the Imperial NIHR Biomedical Research Centre. JK is currently Director of Health Optimisation at the Center for Health and Human Performance (London, UK), as well the co-founder and Medical Director of CERTIFIC.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
cdonnat{at}uchicago.edu
fbunbury{at}carnegiescience.edu
j.kreindler{at}imperial.ac.uk
f.filippidis{at}imperial.ac.uk
a.el-osta{at}imperial.ac.uk
tonu.esko{at}ut.ee
m.harris{at}imperial.ac.uk
↵4 The IFR have been taken from the following data source: https://github.com/mbevand/covid19-age-stratified-ifr
↵5 This calculator can be found at the following link: https://www.dhs.gov/science-and-technology/sars-airborne-calculator
↵6 Link to the EPA website:https://www.epa.gov/expobox/exposure-factors-handbook-chapter-6
↵7 Link to the ASHRAE tables: https://ashrae.iwrapper.com/ASHRAE_PREVIEW_ONLY_STANDARDS/STD_62.1_2019
Data Availability
The links to all datasets used in this study are explicitly provided in the paper.
